These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17345782)

  • 21. Renin inhibition and atherosclerosis.
    Luft FC
    Nephrol Dial Transplant; 2008 Aug; 23(8):2474-6. PubMed ID: 18430802
    [No Abstract]   [Full Text] [Related]  

  • 22. "As time goes by": angiotensin II-mediated transactivation of the EGF receptor comes of age.
    Wolf G
    Nephrol Dial Transplant; 2005 Oct; 20(10):2050-3. PubMed ID: 16166749
    [No Abstract]   [Full Text] [Related]  

  • 23. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S
    Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renin-angiotensin system modulation: instructions for use].
    Bellis A; Rozza F; Crispo S; Trimarco B
    G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term blockade of the renin-angiotensin system: an adequate evaluation is still needed.
    Segura J; Ruilope LM
    Hypertens Res; 2014 Aug; 37(8):701-2. PubMed ID: 24784721
    [No Abstract]   [Full Text] [Related]  

  • 26. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract]   [Full Text] [Related]  

  • 27. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perioperative renin-angiotensin blockade: to continue or discontinue, that is the question!
    Sear JW
    Anesth Analg; 2014 May; 118(5):909-11. PubMed ID: 24781561
    [No Abstract]   [Full Text] [Related]  

  • 30. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL; Townsend RR
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Enhancement of NO bioavailability by ACEI and ARB].
    Fukuo K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():561-6. PubMed ID: 15506449
    [No Abstract]   [Full Text] [Related]  

  • 35. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats.
    Ito N; Ohishi M; Yamamoto K; Tatara Y; Shiota A; Hayashi N; Komai N; Yanagitani Y; Rakugi H; Ogihara T
    Am J Hypertens; 2007 Jul; 20(7):792-9. PubMed ID: 17586415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease.
    Inoue A; Babazono T; Iwamoto Y
    Am J Hypertens; 2008 Mar; 21(3):317-22. PubMed ID: 18202667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual renin-angiotensin system blockade: on the target.
    Robles NR
    Int J Clin Pract; 2008 Aug; 62(8):1134-6. PubMed ID: 18705817
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.